NorthStar Medical Radioisotopes to Host Groundbreaking and Speaker Event Featuring Representatives from the U.S. Department of Energy’s National Nuclear Security Administration and State of Wisconsin

 

WHAT: NorthStar Medical Radioisotopes, in conjunction with Hendricks Holding, will host a groundbreaking and speakers event, “A New Era in U.S. Mo-99 Supply – RadioGenix™ System Approval by the U.S. Food and Drug Administration,” at NorthStar corporate headquarters in Beloit, Wis. The event is to recognize recent FDA approval of the RadioGenixTM System and a groundbreaking ceremony for NorthStar’s new facility to further increase domestic molybdenum-99 production capacity.

Media are invited to attend and photography/videography is permitted.

WHO: Confirmed speakers:

  • Lisa E. Gordon-Hagerty, The U.S. Department of Energy’s Under Secretary for Nuclear Security and Administrator of the National Nuclear Security Administration: “Strengthening Our Nation through Nuclear Security”
  • Rebecca Kleefisch, Wisconsin Lt. Governor
  • Mark R. Hogan, Secretary and CEO, Wisconsin Economic Development Corporation
  • Lori S. Curtis Luther, Beloit City Manager
  • Diane M. Hendricks, Chairman, Hendricks Holding Co., Inc.
  • George Messina, Chairman and Chief Executive Officer, NorthStar Medical Radioisotopes, LLC

 

WHERE: NorthStar Medical Radioisotopes Corporate Headquarters – 1800 Gateway Boulevard, Beloit, Wisconsin 53511

 

WHEN: Tuesday, April 17, 2018. Reporters are invited to attend from 10:15 – 11:30 a.m. for the groundbreaking ceremony and speaker discussions. Media tours are available; please inquire at registration.

Please plan to arrive at 10 a.m. to check in.

 

WHY: The RadioGenixTM System was recently approved by the U.S. Food and Drug Administration. Developed in partnership with the U.S. Department of Energy’s National Nuclear Security Administration, this milestone achievement heralds the first production of molybdenum-99 (Mo-99) in the United States without the use of uranium, eliminating long-lived radioactive and toxic waste products from the production process. Mo-99 is used to generate the important diagnostic imaging radioisotope technetium-99m (Tc-99m), used in more than 40,000 patient studies every day. Ensuring supply for the United States that is produced without proliferation-sensitive highly enriched uranium (HEU) directly supports U.S. national security while helping to ensure a reliable supply of this critical medical radioisotope for patient use.

 

CONTACT:       For more information or if you are a reporter interested in attending, please contact Priscilla Harlan on behalf of NorthStar Medical Radioisotopes, telephone (781) 799-7917, or pharlan@shiningrockllc.com.